Therapeutics - Small Molecule

Company Title Company Description City
AC Thera LLC

AC Thera is developing drugs to neutralize bacterial toxins for the treatment of diseases with high mortality.

Wake Forest
Accord Healthcare Inc.

Accord Healthcare develops and manufactures generic pharmaceuticals. Their portfolio includes therapeutics in oncology, cardiology, neurology, nephrology, urology, psychiatry, diabetes and pain management. The North Carolina location is a sales office.

Achelios Therapeutics Inc.

Achelios Therapeutics develops novel topical therapeutics for the treatment of inflammatory pain, including migraine and temporomandibular joint disorder pain.

Adroit Pharmaceutical Development LLC

Adroit Pharmaceutical Development identifies new and improved formulations and process technologies. Its primary focus is on inhalation and dermatological product development.


AegisCN develops technologies and treatments targeting neurological diseases and inflammation.

Aerie Pharmaceuticals Inc.

Aerie Pharmaceuticals discovers, develops and commercializes first-in-class therapies for the treatment of patients with glaucoma.

Agile Sciences Inc.

Agile Sciences is developing a technology for the treatment of antibiotic-resistant, life-threatening infections.

AimMax Therapeutics Inc.

AimMax Therapeutics researches and develops biopharmaceuticals for the treatment of infection, inflammation and pain through in-licensing or co-development with strategic partners.

Research Triangle Park
Alcami Corporation

Alcami provides contract drug development and manufacturing services, including API manufacturing, formulation development, analytical chemistry and solid dose and parenteral drug manufacturing for both clinical and commercial markets.

ALG Therapeutics LLC

ALG Therapeutics develops pharmaceutical products for pain disorders.

Chapel Hill
AlphaSyx Therapeutics Inc.

AlphaSyx Therapeutics is developing novel medicines that target cholinergic receptors to prevent and treat diseases of inflammation, initially neuroinflammation resulting in Postoperative Cognitive Decline (POCD).

Altavant Sciences

Altavant is developing a treatment for pulmonary arterial hypertension.

Alterna Therapeutics Inc.

Alterna Therapeutics develops therapeutics to treat diabetes and obesity.

Anémot Therapeutics Inc.

Anémot Therapeutics develops therapeutics for acute and chronic inflammation. Its lead product is being developed for severe RSV infections, cystic fibrosis and other diseases of lung injury.

Chapel Hill
Ardeal Pharma Inc.

Ardeal Pharma is a virtual pharma company developing patented stabilized sulforaphane for the dermal pharmaceutical and cosmetic markets.

Ardeal Research Institute

Ardeal Research Institute is a non-profit organization that develops drug discovery capabilities of the natural resources in Western North Carolina. The Institute has collaboration agreements in place with Brevard College and the N.C. Arboretum.

Array BioPharma Inc.

Array BioPharma discovers, develops and commercializes targeted, small-molecule drugs to treat cancer.

Arrivo BioVentures LLC

Arrivo BioVentures accelerates biologics and small molecules from IND/phase one through proof-of-concept, with biologics in development for dermatologic conditions and hearing loss.


Asinex designs small-molecule libraries and provides lead optimization, custom synthesis and other chemistry services. The Winston-Salem location is the company's U.S. headquarters.

Aspir-Tek Inc.

Aspir-Tek makes Aquaprin, an FDA-approved water-soluble aspirin.

Rocky Mount
Atox Bio Inc.

Atox Bio develops novel immunomodulators to treat critically ill patients. Initial focus is on patients with Necrotizing Soft Tissue Infections.

Chapel Hill
Aurobindo Pharma USA Inc.

Aurobindo Pharma is a generic drug manufacturer. Aurobindo develops inhalation and dermatological products from the company's U.S. research and development headquarters in North Carolina.

Avior Inc.

Avior Bio is an developing a nanoparticle-based drug delivery technology to deliver lipophilic drugs with high bioavailability. It is testing its technology using a molecule for the treatment of pruritus in chronic kidney disease.

Holly Springs
Avista Pharma Solutions

Avista Pharma Solutions provides pharmaceutical, animal health and medical device clients with services including API and drug product discovery, development and cGMP manufacturing and stand-alone analytical and microbiology testing support.

Avolynt Inc.

Avolynt is developing a novel SGLT2 inhibitor for the treatment of nonalcoholic steatohepatitis (NASH) and type 2 diabetes.

Research Triangle Park
Ballek Biologics LLC

Ballek Biologics is developing a therapeutic to reverse opioid overdose.

Banner Life Sciences LLC

Banner Life Sciences develops formulation technologies (gelcaps, tablets and sterile injectables) and licenses and markets prescription, over-the-counter and nutritional products.

High Point
Barbaresco Pharma LLC

Barbaresco Pharmaceuticals is a target drug discovery company focused on obesity, cardiovascular and metabolic diseases.

Chapel Hill
BestCo Inc.

BestCo manufactures confectionery-based dosage forms for nonprescription drug products and dietary supplements.

BioAgilytix Labs Inc.

BioAgilytix is a bioanalytical lab specializing in large-molecule bioanalysis, offering PK, immunogenicity, biomarkers and cell-based assays in support of the development and release testing of biologics and small-molecule therapeutics.

BioCryst Pharmaceuticals Inc.

BioCryst Pharmaceuticals designs and develops novel, small-molecule oral drugs that block key enzymes to treat rare diseases. The Durham location houses BioCryst's clinical, regulatory and executive teams.

BioDelivery Sciences International Inc.

BioDelivery Sciences is a specialty pharmaceutical company with a focus in the areas of pain management and addiction. The company's lead products utilize a buccal film delivery system.


Biogen discovers, develops and manufactures therapies for serious neurological and neurodegenerative diseases. It operates biologics and oral solid dose manufacturing facilities and a patient services contact center in RTP.

Research Triangle Park
Biogen (Oral Solid Dose Facility)

Biogen discovers, develops and manufactures therapies for serious neurological and neurodegenerative diseases. This site manufactures oral solid dose products.

Research Triangle Park
BioKier Inc.

BioKier develops proprietary adjuvant treatments for diabetes and related disorders. BioKier has identified a therapeutic opportunity based on gastric bypass surgery and is developing a novel treatment for diabetes.

Chapel Hill
BioMarck Pharmaceuticals Ltd.

BioMarck develops drugs to treat pulmonary diseases and disorders, such as chronic obstructive pulmonary disease, ARDS, cystic fibrosis and lung cancer.

Bionpharma Inc.

Bionpharma partners with pharmaceutical companies to in-license, out-license, develop, manufacture and distruibute generic and over-the-counter products. Its Raleigh location is a sales office.

Blue Ridge Institute for Medical Research

Blue Ridge Institute for Medical Research (BRIMR) researches small-molecule inhibitors of protein kinases and targeted cancer therapies.

Horse Shoe
Cancer Advances Inc.

Cancer Advances, a subsidiary of Cato Bioventures, develops immunomodulator therapeutics to treat gastrointestinal cancers.

Capture Pharmaceuticals Inc.

Capture Pharmaceuticals develops oral treatments for removing toxic or radioactive metals in contaminated individuals.

Chapel Hill
CardioPharma Inc.

CardioPharma develops combinatorial products to treat cardiovascular disease.

Catalent Pharma Solutions LLC

Catalent provides drug development and manufacturing services for the pharma, biotech and consumer sectors. Core offerings include biologics, parenterals, oral solids, softgel, inhalation, clinical supply services and analytical services.

Cereius Inc.

Cereius is developing novel radio-labeled therapeutics for treating solid tumor brain metastasis.

Chaperone Therapeutics Inc.

Chaperone Therapeutics develops disease-modifying therapies for neurodegenerative and rare diseases caused by protein misfolding.

Chapel Hill
Chiesi USA Inc.

Chiesi USA, the U.S. affiliate of Chiesi Farmaceutici S.p.A, develops and commercializes products in the therapeutic areas of respiratory, cardiovascular, neonatology and cystic fibrosis.

Cloud Pharmaceuticals Inc.

Cloud Pharmaceuticals designs and develops novel drug molecules using computational design for a wide range of therapeutic areas including cancer, inflammation, CNS disorders and rare diseases.

Research Triangle Park
CMP Pharma Inc.

CMP develops, manufactures and commercializes specialty pharmaceuticals, focused on niche liquid and topical products that solve unmet patient needs.

Cognosci Inc.

Cognosci develops neurorestorative therapies for Alzheimer's disease, multiple sclerosis, traumatic brain injury, nerve crush and other disease and trauma indications.

Collaborations Pharmaceuticals Inc.

Collaborations Pharmaceuticals develops drugs for rare and neglected diseases using machine learning software, providing preclinical and clinical expertise to rare disease foundations, academic scientists and companies developing clinical candidates.

Countervail Corp.

Countervail develops and commercializes products to protect against and treat exposure to chemical weapons and pesticide poisoning.

Curl Bio LLC

Curl Bio develops drugs for the interrelated set of disorders involving Type 2 diabetes, obesity, fatty liver disease, metabolic syndrome and associated complications.

David H. Murdock Research Institute

The David H. Murdock Research Institute (DHMRI) provides collaborators with genomics, proteomics, metabolomics, light microscopy, NMR, clinical chemistry, cellular biology and immunology services. DHMRI focuses on human health, nutrition and agriculture.

Dermavant Sciences

Dermavant, a part of the Roivant family of companies, develops therapies for the treatment of skin diseases.

Dignify Therapeutics LLC

Dignify Therapeutics develops bladder and bowel drug therapies for spinal cord-injured, multiple sclerosis and similar patient populations with voiding dysfunction.

Research Triangle Park
Dina Pharmaceuticals Inc.

Dina Pharmaceuticals is developing a treatment for Levodopa-Induced Dyskinesia (LID) associated with Parkinson’s disease.

DMK Pharmaceuticals Inc.

DMK Pharmaceuticals develops small-molecule analgesics that have reduced side effects, such as abuse potential, respiratory depression, nausea, vomiting and itching, that are currently associated with marketed analgesics.

Holly Springs
Dova Pharmaceuticals Inc.

Dova Pharmaceuticals develops treatments for orphan diseases. Its lead compound is being developed as a treatment for thrombocytopenia in patients with chronic liver disease.

Ei, A Pharmaceutical SolutionWorks

Ei develops and manufactures liquid, semisolid and powder prescription and nonprescription skincare and animal health products.

Eisai Inc.

Eisai discovers, develops and markets pharmaceuticals in neurology and oncology-critical care. This site supports global partnerships, quality assurance and supply chain for the company.

Emergo Therapeutics Inc.

Emergo Therapeutics is repurposing drugs for the treatment of acute inflammation.

EncepHeal Therapeutics Inc.

EncepHeal Therapeutics develops neurotherapeutics to treat substance abuse and mental health disorders through working partnerships with academic institutions, private companies and foundations and government agencies.

ENCO Pharmaceutical Development Inc.

ENCO Pharmaceutical Development Inc. (EPDI) provides comprehensive product development services to the pharmaceutical and medical device market.

Endacea Inc.

Endacea develops A1 adenosine receptor antagonists as drug candidates for renal impairment and inflammation, including sepsis and asthma.

Research Triangle Park
EnDev Laboratories

EnDev offers topical research and development services for therapeutic skin care and prescription dermatological products. Services include formulation and process development, analytical development, technology transfer and regulatory solutions.

ENVIGEN Pharmaceuticals Inc.

ENVIGEN develops classes of small drug-like molecules to treat life-threatening diseases including cancer, HIV/AIDS and neurological disorders.

EpiZyme Inc.

Epizyme discovers, develops and plans to commercialize innovative personalized therapeutics for patients with genetically defined cancers.

Eppin Pharma Inc.

Eppin Pharma is developing a non-hormonal male oral contraceptive.

Evecxia Inc.

Evecxia is developing and commercializing a drug to treat patients suffering from neuropsychiatric conditions for which current therapies are inadequate.

Exela Pharma Sciences LLC

Exela Pharma Sciences develops, manufactures and markets sterile injectable pharmaceuticals. The Lenoir site is a sterile manufacturing facility, compliant with cGMP and other FDA regulations.

Exodos Life Science Partners

Exodos Life Sciences advances product concepts through the 505(b)(2) process to early clinical proof-of-principle and sale. Exodus specializes in topical formulations for the treatment of pain and inflammation, cold sores and nail fungis.

Chapel Hill
Eyedesis Biosciences LLC

Eyedesis Biosciences is developing a small-molecule macrophage inhibitor for the treatment of neovascular age related macular degeneration.

Chapel Hill
Fennec Pharmaceuticals Inc.

Fennec Pharmaceuticals develops a sodium thiosulfate formula for the prevention of ototoxicity from cisplatin in pediatric patients.

Research Triangle Park
Fervent Pharmaceuticals LLC

Fervent Pharmaceuticals develops a nonhormonal product, FP-101, to treat vasomotor symptoms associated with menopause.

FHI 360

FHI 360 is a nonprofit human development organization that focuses on family planning, reproductive health and HIV/AIDs by advancing locally-driven solutions. The laboratory in Durham offers medical device and pharmaceutical testing services.

FibroStatin Inc.

FibroStatin develops treatments for drug resistant cancer and organ fibrosis using its proprietary GPBP technology that has identified a novel and preferred pathway for inhibiting the cell epithelial-to-mesenchymal transition (EMT).

FLAG Therapeutics Inc.

FLAG Therapeutics develops cancer therapeutics using new classes of small molecules which have selective dual activity: antiangiogenesis and chemotherapeutic.

FUJIFILM Diosynth Biotechnologies USA Inc.

Fujifilm Diosynth Biotechnologies provides biologics contract development and manufacturing. Services include cell line development, process and analytical development, clinical and commercial manufacturing and bioprocess research and development.

G&W Laboratories LLC

G&W Laboratories manufactures OTC and prescription hydrocortisone, antifungal and permethrin products as creams, ointments, liquids and suppositories.

G1 Therapeutics Inc.

G1 Therapeutics develops small-molecule therapies to address significant unmet needs in oncology.

Research Triangle Park
GBM Pharma Inc.

GBM Pharma develops drugs for the treatment of glioblastoma multiforme.

Genebiology Inc.

GeneBiology identifies, patents and develops new parenteral formulations of approved drugs for unmet medical needs using the 505b2 regulatory pathway.

Research Triangle Park
Generys Biopharmaceuticals Corp.

Generys BioPharmaceuticals develops drugs, formulations and generics for unmet medical needs. Generys also offers therapeutic pipeline portfolio consulting and management services on a contract basis.

Chapel Hill
Glenmark Pharmaceuticals Inc., USA

Glenmark Pharmaceuticals discovers small-molecule drugs and biologics in the areas of oncology, respiratory disease and dermatology, and manufactures and distributes APIs and generics. The Monroe site manufactures oral solids, injectables and topicals.


GlaxoSmithKline develops and manufactures vaccines, medicines and consumer healthcare products for the treatment of infectious and respiratory diseases, central nervous system disorders, immuno-inflammation, diabetes and cancer.

Research Triangle Park
GSK (Zebulon)

GlaxoSmithKline manufactures solid-dose products, including tablets and capsules, at its Zebulon facility. The plant also does granulation, drying and packaging, and contract manufacturing of antibiotics for other companies.

Gyrus Pharmaceuticals Inc.

Gyrus Pharmaceuticals is developing treatments for serious diseases of the central nervous system using proprietary therapeutic agents and nanoparticles for noninvasive delivery to the CNS.

Chapel Hill
Hammock Pharmaceuticals Inc.

Hammock Pharmaceuticals licenses and develops women's health and urology products. It is developing a metronidazole and clindamycin vaginal gel for the treatment of bacterial vaginosis, and a urology product for the treatment of radiation cystitis.

Hemodynamic Therapeutics

Hemodynamic Therapeutics develops a small-molecule combination therapy for obesity-related hypertension.

Icagen Inc.

Icagen partners with global pharmaceutical and biotech companies to generate high-quality, advanced leads, with expertise in kinases, GPCR’s, ion channels and transporters.

Indicus Pharma LLC

Indicus develops generic formulations in oral solid dosage forms, parenterals and ophthalmics. Products are manufactured at a partner facility in India.

Innocrin Pharmaceuticals Inc.

Innocrin discovers and develops a novel small-molecule CYP17 lyase inhibitor that can be taken orally to treat castration-resistant prostate cancer.

Innovate Biopharmaceuticals Inc.

Innovate Biopharmaceuticals is developing novel medicines for autoimmune/inflammatory disease.

Invitrox Inc.

Invitrox provides GLP-compliant bioanalytical services for nonclinical and clinical drug development studies, with expertise in method development and validation, small and large molecules, sample analysis, metabolites, biomarkers and drug monitorining.

Research Triangle Park
Karamedica Inc.

Karamedica has developed a plasma treatment system to decontaminate chitosan, a biopolymer found in the shells of shrimps and crabs. Additionally, Karemedica is developing medical devices and drug delivery systems using chitosan.

Kowa Research Institute Inc.

Kowa Research Institute, a division of Kowa Company Ltd., develops therapeutic drugs for the treatment of cardio-metabolic diseases such as diabetes and atherosclerosis, pain and sensory organ disorders.

Krenitsky Pharmaceuticals Inc.

Krenitsky Pharmaceuticals discovers and develops drug candidates, with a focus on disorders of the nervous system.

Chapel Hill

Krka is a generic pharmaceuticals manufacturer headquartered in Slovenia. The Wilmington office is the US business office of Krka.

KXTbio Inc.

KXTbio develops and commercializes reagents and assays for two major classes of drug targets, GTPases and G protein-coupled receptors.

Chapel Hill
Lundbeck NA Ltd.

Lundbeck is a pharmaceutical development company that acquires and develops products for the treatment of various human diseases, including central nervous system disorders.

MAA Laboratories Inc.

MAA Laboratories is reformulating and commercializing existing proprietary anti-cancer small molecules, with the purpose of enhancing therapeutic efficiency for targeted drug delivery and mitigating undesirable effects of currently approved drugs.